SMTK Form 4: Barbra Keck Receives 71,077-Share Option Grant
Rhea-AI Filing Summary
Insider grant and holdings summary: SmartKem CFO Barbra Keck was granted a stock option on 09/03/2025 giving the right to buy 71,077 shares of common stock at an exercise price of $1.16 per share. The option is exercisable through 09/03/2035. Following the grant, Keck beneficially owns 71,077 underlying shares, held directly. The option vests 25% at grant with the remainder vesting in equal monthly installments over 36 months beginning 09/03/2025, with monthly vesting on the 3rd.
Positive
- Time-based vesting aligns the CFO with long-term shareholder value through a 25% immediate vest and monthly vesting over 36 months
- Clear disclosure of option terms: grant date, number of shares, exercise price ($1.16), and expiration date (09/03/2035)
Negative
- Potential dilution from 71,077 shares exists but cannot be sized because total outstanding shares are not provided in this filing
- No grant-date fair value or issuer-level context is included, so compensation expense impact is not assessable from this form alone
Insights
TL;DR: CFO received a standard multi-year option grant with time-based vesting, aligning incentives but not evidently material to shareholders.
The grant is a time-based equity award that vests 25% at grant and then monthly over three years, which is typical for executive compensation to promote retention and alignment with shareholder interests. The reported stake is limited to the option underlying 71,077 shares at a modest exercise price of $1.16. The filing is routine and contains no indications of accelerated vesting, related-party transactions beyond the executive role, or disposal activity. Impact appears procedural rather than transformative.
TL;DR: Award structure encourages retention; dilution and expense depend on company share count and accounting treatment, not disclosed here.
The option term to 2035 and staged vesting over 36 months is consistent with retention-focused grants. While the absolute number of shares (71,077) and the exercise price ($1.16) are disclosed, the filing lacks the issuer's total outstanding share count or grant-date fair value, so the relative dilution and accounting expense cannot be assessed. No sales or exercises were reported.